Managing the Burden of Diabetes Among Employers and Employees
Despite effective care guidelines,
adherence remains low
Given the unrelenting obesity epidemic, diabetes will continue as one of the most prevalent and disabling chronic conditions in America. Like many other chronic diseases, diabetes has a major impact on productivity, disability, and health care costs. Unfortunately, diabetes cannot be cured or managed by pharmaceuticals alone. Effective diabetes management requires the active engagement and participation of the patient with their doctor.
The American Diabetes Association (ADA) has specified a clear set of evidence-based care standards that all patients with diabetes should follow annually. Unfortunately, despite these proven effective care guidelines, most people with diabetes have very low adherence to recommended standards of care (i.e. “gaps in care”) as well as low rates of compliance with regular blood glucose testing and recommended medication use
National Diabetes Statistics
with Medication Regimen
Claims Attributed to
Members with Diabetes
Proving the hypotheses
a compared controlled study of effectiveness
Abacus Health Solutions conducted a comparative controlled study of the Program’s effectiveness. A retrospective, pre-post-comparative study was conducted using propensity score matching to compare utilization and cost data between individuals enrolled versus a matched group of individuals eligible but not enrolled in the Program from 2010 to 2017.
A cohort of 3,318 members was identified; 1,659 of which were enrolled in the Program and the control cohort consisted of another 1,659 individuals that were eligible for the program but did not enroll and were matched on several demographic and health status and health risk variables, like age, gender, location and insulin use, as well as, the Elixhauser Comorbidity Index (a measure of a person’s risk of hospital admission calculated based on the presence or absence of a set of chronic medical conditions) helped ensure we were comparing members who had similar health risks and illness severity prior to program implementation.
Download the Full
Improvement in Clinical Outcomes,
Service Utilization, and Costs
Program participants had more recommended testing, including 32% more adherence to semi-annual HbA1c testing, 9% greater lipid panel testing, and 38% greater adherence to microalbumin lab testing.
Among the highest risk members, a 20.1% decrease in members with a HbA1c of >9.
Participants had an 80% greater likely hood of continuing Insulin usage.
Participants had 54% more physician visits, a 54% reduction in hospital admissions, and a 34% reduction in hospital days stay.
Once adjusted for baseline differences, the participants demonstrated lower medical costs and greater pharmacy costs versus matched controls during the comparison period.
Decrease in Medical Spending PMPMParticipants vs Non Participants
$1,556.40 Decrease in PMPY medical spending